Last updated: March 13, 2026
What is NDC 00480-3475?
NDC 00480-3475 corresponds to Ibrutinib (Imbruvica), a targeted therapy used primarily for treating various hematologic malignancies including mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and Waldenström's macroglobulinemia. Marketed by Pharmacyclics and Janssen, ibrutinib is an oral Bruton's tyrosine kinase (BTK) inhibitor.
Market Overview
Sales Volume and Revenue
2022 sales for ibrutinib reached approximately $4.2 billion globally, with the U.S. accounting for roughly 70% of sales. Sales growth has stabilized but shows slow expansion driven by new indications, combination therapies, and biosimilar competition.
Key Market Drivers
- High efficacy in relapsed/refractory B-cell malignancies.
- Expanding approved indications, including marginal zones and specific lymphomas.
- Growing adoption in combination regimens with other novel agents.
Competitive Landscape
| Drug |
Mechanism |
Approximate U.S. Sales (2022) |
Approval Year |
| Ibrutinib (Imbruvica) |
BTK inhibitor |
$2.9 billion |
2013 |
| Acalabrutinib (Calquence) |
Second-generation BTK inhibitor |
$560 million |
2017 |
| Zanubrutinib (Brukinzi) |
Second-generation BTK inhibitor |
Estimated $400 million |
2019 |
Biosimilar and generic entry remains limited due to patent protections and formulation complexity, prolonging exclusivity.
Patent and Regulatory Status
The primary patent for ibrutinib extends into 2030 in the U.S., with multiple orphan and method-of-use patents filed. Patent challenges and lawsuits could influence market entry timing for biosimilars.
Price Trends and Projections
Current Pricing
In 2022, the average wholesale price (AWP) per 140 mg capsule was approximately $1,200. The annual treatment cost varies by indication but averages between $140,000 and $180,000 per patient in the U.S.
Cost Dynamics
- Drug price increases have been modest, averaging 2-3% annually over the past five years.
- Discounting and rebates influence net prices, with significant negotiation ability held by payers.
Price Projections (2023-2027)
| Year |
Expected Average Wholesale Price (per 140 mg capsule) |
Remarks |
| 2023 |
$1,210 |
Stable price, minor increases |
| 2024 |
$1,240 |
No significant patent challenges, continued demand |
| 2025 |
$1,260 |
Entry of second-generation agents, possible slight price pressure |
| 2026 |
$1,280 |
Market penetration of biosimilars may influence price |
| 2027 |
$1,300 |
Patent expiry still anticipated in late 2029-2030, prices may plateau or decline |
Influencing Factors
- Patent litigation outcomes may lead to price pressure before patent expiry.
- Emergence of generics or biosimilars would significantly reduce prices.
- Market penetration of other BTK inhibitors could affect demand and pricing strategies.
Future Market Potential
The pipeline includes next-generation BTK inhibitors and combination regimens that could extend the drug's market lifespan. The increased use of ibrutinib in first-line settings and broader indications may sustain sales but also pressure prices through negotiations.
Key Market Risks
- Patent expiration risks in late 2029 or early 2030.
- Competitive entry from biosimilars or alternative therapies.
- Regulatory modifications affecting reimbursement models.
Conclusion
Ibrutinib's market remains robust, driven by high efficacy and expanding indications. Its pricing is expected to be stable, with slight increases until patent expiration, after which significant price erosion may occur owing to biosimilar competition.
Key Takeaways
- Total global sales reached approximately $4.2 billion in 2022.
- Current average wholesale price around $1,200 per capsule.
- Market projected to maintain stability through 2027, barring patent litigation or biosimilar entry.
- Patent protection lasts until approximately 2030, delaying significant price declines.
- Market growth may slow due to increasing competition and biosimilars.
FAQs
1. When will biosimilars for ibrutinib become available in the U.S.?
Biosimilar approval is expected around 2029-2030, contingent on patent litigation outcomes and regulatory review.
2. How does ibrutinib compare cost-wise to its competitors?
Pricing per capsule is similar across the second-generation BTK inhibitors; however, newer agents may have different dosing, efficacy, or side-effect profiles influencing overall treatment costs.
3. What are the primary drivers for sales growth or decline?
Expansion into new indications, combination regimens, and potential biosimilar entry are primary drivers influencing sales.
4. How do patent protections impact pricing strategies?
Patent protections allow for pricing stability and premium pricing; expiry invites competition, leading to price reductions.
5. What is the outlook for future price adjustments?
Prices are likely to increment modestly until patent expiration; post-patent, prices are expected to decline significantly with generic/biosimilar entry.
References
- IQVIA. (2022). Pharmaceutical Market Reports.
- U.S. Food and Drug Administration. (2022). Drug Approval and Patent Data.
- Bloomberg Intelligence. (2023). Oncology Market Analysis.
- Janssen Pharmaceuticals. (2022). Product Information and Pricing.
- National Comprehensive Cancer Network (NCCN). (2023). Guidelines for CLL and Mantle Cell Lymphoma.
